216 related articles for article (PubMed ID: 21878903)
1. Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial.
Kang HJ; Bartholomae CC; Paruzynski A; Arens A; Kim S; Yu SS; Hong Y; Joo CW; Yoon NK; Rhim JW; Kim JG; Von Kalle C; Schmidt M; Kim S; Ahn HS
Mol Ther; 2011 Nov; 19(11):2092-101. PubMed ID: 21878903
[TBL] [Abstract][Full Text] [Related]
2. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease.
Roesler J; Brenner S; Bukovsky AA; Whiting-Theobald N; Dull T; Kelly M; Civin CI; Malech HL
Blood; 2002 Dec; 100(13):4381-90. PubMed ID: 12393624
[TBL] [Abstract][Full Text] [Related]
3. Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation.
Sadat MA; Dirscherl S; Sastry L; Dantzer J; Pech N; Griffin S; Hawkins T; Zhao Y; Barese CN; Cross S; Orazi A; An C; Goebel WS; Yoder MC; Li X; Grez M; Cornetta K; Mooney SD; Dinauer MC
Gene Ther; 2009 Dec; 16(12):1452-64. PubMed ID: 19657370
[TBL] [Abstract][Full Text] [Related]
4. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease.
Dinauer MC; Li LL; Björgvinsdóttir H; Ding C; Pech N
Blood; 1999 Aug; 94(3):914-22. PubMed ID: 10419882
[TBL] [Abstract][Full Text] [Related]
5. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells.
Santilli G; Almarza E; Brendel C; Choi U; Beilin C; Blundell MP; Haria S; Parsley KL; Kinnon C; Malech HL; Bueren JA; Grez M; Thrasher AJ
Mol Ther; 2011 Jan; 19(1):122-32. PubMed ID: 20978475
[TBL] [Abstract][Full Text] [Related]
6. Efficient retroviral transduction of human bone marrow progenitor and long-term culture-initiating cells: partial reconstitution of cells from patients with X-linked chronic granulomatous disease by gp91-phox expression.
Porter CD; Parkar MH; Collins MK; Levinsky RJ; Kinnon C
Blood; 1996 May; 87(9):3722-30. PubMed ID: 8611697
[TBL] [Abstract][Full Text] [Related]
7. Simian immunodeficiency virus lentivector corrects human X-linked chronic granulomatous disease in the NOD/SCID mouse xenograft.
Naumann N; De Ravin SS; Choi U; Moayeri M; Whiting-Theobald N; Linton GF; Ikeda Y; Malech HL
Gene Ther; 2007 Nov; 14(21):1513-24. PubMed ID: 17728796
[TBL] [Abstract][Full Text] [Related]
8. Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease.
Brendel C; Rothe M; Santilli G; Charrier S; Stein S; Kunkel H; Abriss D; Müller-Kuller U; Gaspar B; Modlich U; Galy A; Schambach A; Thrasher AJ; Grez M
Hum Gene Ther Clin Dev; 2018 Jun; 29(2):69-79. PubMed ID: 29664709
[TBL] [Abstract][Full Text] [Related]
9. Correction of respiratory burst activity in X-linked chronic granulomatous cells to therapeutically relevant levels after gene transfer into bone marrow CD34+ cells.
Becker S; Wasser S; Hauses M; Hossle JP; Ott MG; Dinauer MC; Ganser A; Hoelzer D; Seger R; Grez M
Hum Gene Ther; 1998 Jul; 9(11):1561-70. PubMed ID: 9694155
[TBL] [Abstract][Full Text] [Related]
10. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.
Kang EM; Choi U; Theobald N; Linton G; Long Priel DA; Kuhns D; Malech HL
Blood; 2010 Jan; 115(4):783-91. PubMed ID: 19965657
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy of chronic granulomatous disease.
Grez M; Becker S; Saulnier S; Knöss H; Ott MG; Maurer A; Dinauer MC; Hoelzer D; Seger R; Hossle JP
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S99-104. PubMed ID: 10933200
[TBL] [Abstract][Full Text] [Related]
12. Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker.
Sadat MA; Pech N; Saulnier S; Leroy BA; Hossle JP; Grez M; Dinauer MC
Hum Gene Ther; 2003 May; 14(7):651-66. PubMed ID: 12804147
[TBL] [Abstract][Full Text] [Related]
13. High-level reconstitution of respiratory burst activity in a human X-linked chronic granulomatous disease (X-CGD) cell line and correction of murine X-CGD bone marrow cells by retroviral-mediated gene transfer of human gp91phox.
Ding C; Kume A; Björgvinsdóttir H; Hawley RG; Pech N; Dinauer MC
Blood; 1996 Sep; 88(5):1834-40. PubMed ID: 8781441
[TBL] [Abstract][Full Text] [Related]
14. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.
Chiriaco M; Farinelli G; Capo V; Zonari E; Scaramuzza S; Di Matteo G; Sergi LS; Migliavacca M; Hernandez RJ; Bombelli F; Giorda E; Kajaste-Rudnitski A; Trono D; Grez M; Rossi P; Finocchi A; Naldini L; Gentner B; Aiuti A
Mol Ther; 2014 Aug; 22(8):1472-1483. PubMed ID: 24869932
[TBL] [Abstract][Full Text] [Related]
15. Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells.
Brenner S; Whiting-Theobald NL; Linton GF; Holmes KL; Anderson-Cohen M; Kelly PF; Vanin EF; Pilon AM; Bodine DM; Horwitz ME; Malech HL
Blood; 2003 Oct; 102(8):2789-97. PubMed ID: 12829597
[TBL] [Abstract][Full Text] [Related]
16. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
17. Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.
Kaufmann KB; Brendel C; Suerth JD; Mueller-Kuller U; Chen-Wichmann L; Schwäble J; Pahujani S; Kunkel H; Schambach A; Baum C; Grez M
Mol Ther; 2013 Mar; 21(3):648-61. PubMed ID: 23207695
[TBL] [Abstract][Full Text] [Related]
18. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
Ott MG; Schmidt M; Schwarzwaelder K; Stein S; Siler U; Koehl U; Glimm H; Kühlcke K; Schilz A; Kunkel H; Naundorf S; Brinkmann A; Deichmann A; Fischer M; Ball C; Pilz I; Dunbar C; Du Y; Jenkins NA; Copeland NG; Lüthi U; Hassan M; Thrasher AJ; Hoelzer D; von Kalle C; Seger R; Grez M
Nat Med; 2006 Apr; 12(4):401-9. PubMed ID: 16582916
[TBL] [Abstract][Full Text] [Related]
19. [Gene therapy for inherited diseases using heamatopoietic stem cells--gene therapy for patients with chronic granulomatous disease].
Nunoi H; Ishibashi F
Hum Cell; 1999 Sep; 12(3):103-8. PubMed ID: 10695016
[TBL] [Abstract][Full Text] [Related]
20. Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.
Brendel C; Hänseler W; Wohlgensinger V; Bianchi M; Tokmak S; Chen-Wichmann L; Kuzmenko E; Cesarovic N; Nicholls F; Reichenbach J; Seger R; Grez M; Siler U
Hum Gene Ther Methods; 2013 Jun; 24(3):151-9. PubMed ID: 23489116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
